When developing new therapeutics and especially complex modalities, a series of challenges and risks typically arise. One such risk is unwanted immunogenicity, which can lead to decreased efficacy and safety. Click to listen to this insightful talk with our expert, Sofie Pattyn, CTO and founder of ImmunXperts, a Q2 Solutions Company, who discusses how today’s tools and strategies that can improve and accelerate therapeutic drug development in an early stage.